Can you take Atgam with Avatrombopag?
No drug interactions found, but 9 warnings to review for the following 2 drugs:
- Atgam (lymphocyte immune globulin, anti-thy (equine))
- avatrombopag
Drug interactions
There were no interactions found between Atgam and avatrombopag. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.
Food/lifestyle interactions
Moderate food/lifestyle interactions
Moderate:
avatrombopag Food/Lifestyle
Applies to: avatrombopag
Taking avatrombopag with food helps ensure consistent absorption of the medication into the blood stream.
You should take each dose of avatrombopag with food at the same time everyday.
Disease interactions
8 potential interactions Applies to: 7 conditions, including Thrombotic/Thromboembolic Disorder, Liver Disease, Immunodeficiency, Renal Dysfunction, and History, Thrombotic/Thromboembolic Disorder.
History, Thrombotic/Thromboembolic Disorder
Moderate:
avatrombopag
Avatrombopag has a moderate potential interaction with History, Thrombotic/Thromboembolic Disorder.
Thromboembolic complications may result from increases in platelet counts with TPO receptor agonists such as avatrombopag, lusutrombopag, and eltrombopag. Consider the potential for increased risk of thromboembolism when administering these medications to patients with known risk factors for thromboembolism, including genetic prothrombotic conditions (Factor V Leiden, Prothrombin 20210 A, Antithrombin deficiency or Protein C or S deficiency).
Immunodeficiency
Moderate:
Atgam
The lymphocyte immune globulin, anti-thy (equine) in Atgam has a moderate potential interaction with Immunodeficiency.
Do not administer live vaccines to patients about to receive, receiving, or after treatment with lymphocyte immune globulin, anti-thy (equine). Concomitant administration of lymphocyte immune globulin, anti-thy (equine) with live virus vaccines carries a potential of uncontrolled viral replication in the immunosuppressed patient. There is insufficient information to fully define the extent of the risk, or the period of time during which the risk exists. If administered, live viruses may interfere with lymphocyte immune globulin, anti-thy (equine) treatment.
Liver Disease
Moderate:
Atgam
The lymphocyte immune globulin, anti-thy (equine) in Atgam has a moderate potential interaction with Liver Disease.
The use of lymphocyte immune globulin, anti-thy (equine) in patients with aplastic anemia and other hematologic abnormalities may result in abnormal tests of liver function (SGOT, SGPT, alkaline phosphatase) and renal function (serum creatinine). It is recommended to evaluate these tests closely in these patients.
Protein C Deficiency
Moderate:
avatrombopag
Avatrombopag has a moderate potential interaction with Protein C Deficiency.
Thromboembolic complications may result from increases in platelet counts with TPO receptor agonists such as avatrombopag, lusutrombopag, and eltrombopag. Consider the potential for increased risk of thromboembolism when administering these medications to patients with known risk factors for thromboembolism, including genetic prothrombotic conditions (Factor V Leiden, Prothrombin 20210 A, Antithrombin deficiency or Protein C or S deficiency).
Renal Dysfunction
Moderate:
Atgam
The lymphocyte immune globulin, anti-thy (equine) in Atgam has a moderate potential interaction with Renal Dysfunction.
The use of lymphocyte immune globulin, anti-thy (equine) in patients with aplastic anemia and other hematologic abnormalities may result in abnormal tests of liver function (SGOT, SGPT, alkaline phosphatase) and renal function (serum creatinine). It is recommended to evaluate these tests closely in these patients.
Moderate:
avatrombopag
Avatrombopag has a moderate potential interaction with Renal Dysfunction.
The effect of severe renal impairment (CrCl < 30 mL/min) including patients requiring hemodialysis on avatrombopag pharmacokinetics is unknown. Caution and monitoring is advised.
Thrombotic/Thromboembolic Disorder
Moderate:
avatrombopag
Avatrombopag has a moderate potential interaction with Thrombotic/Thromboembolic Disorder.
Thromboembolic complications may result from increases in platelet counts with TPO receptor agonists such as avatrombopag, lusutrombopag, and eltrombopag. Consider the potential for increased risk of thromboembolism when administering these medications to patients with known risk factors for thromboembolism, including genetic prothrombotic conditions (Factor V Leiden, Prothrombin 20210 A, Antithrombin deficiency or Protein C or S deficiency).
Vaccination
Moderate:
Atgam
The lymphocyte immune globulin, anti-thy (equine) in Atgam has a moderate potential interaction with Vaccination.
Do not administer live vaccines to patients about to receive, receiving, or after treatment with lymphocyte immune globulin, anti-thy (equine). Concomitant administration of lymphocyte immune globulin, anti-thy (equine) with live virus vaccines carries a potential of uncontrolled viral replication in the immunosuppressed patient. There is insufficient information to fully define the extent of the risk, or the period of time during which the risk exists. If administered, live viruses may interfere with lymphocyte immune globulin, anti-thy (equine) treatment.
Report options
More resources
Atgam
A total of 181 drugs are known to interact with Atgam.
- Atgam is in the drug class selective immunosuppressants.
- Atgam is used to treat the following conditions:
avatrombopag
A total of 98 drugs are known to interact with avatrombopag.
- Avatrombopag is in the drug class platelet-stimulating agents.
- Avatrombopag is used to treat the following conditions:
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.